<DOC>
	<DOCNO>NCT02202213</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability Lu AF11167 patient schizophrenia follow various repeat dose regimen Lu AF11167 ( alone add treatment risperidone ) .</brief_summary>
	<brief_title>Safety Tolerability Study Lu AF11167 After Repeated Dosing Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Man woman age ≥18 year ≤60 year body mass index ( BMI ) ≥18.5 ≤38 m2 Primary diagnosis schizophrenia accord DSMIVTR™ ( cod 295.10 , 295.20 , 295.30 , 295.90 ) Clinical Global Impression Severity Illness ( CGIS ) score ≤4 ( moderately ill ) Screening Visit Baseline Visit ( Day 1 ) PANSS total score ≤80 Screening Visit Baseline Visit ( Day 1 ) Score 4 ( moderate ) follow PANSS item Screening Visit Baseline Visit ( Day 1 ) : P7 ( hostility ) , G8 ( uncooperativeness ) Minimal level extrapyramidal sign , define score ≤5 ( moderately severe ) four Clinical Global Impression Severity ( CGIS ) item ESRSA ; parkinsonism , akathisia , dystonia , tardive dyskinesia Screening Visit Baseline Visit Willingness hospitalise approximately 3 week Baseline Visit ( Day 1 ) The patient experience acute exacerbation require hospitalization within last 6 month The patient experience acute exacerbation require increase antipsychotic medication ( reference drug dose ) within last 4 week Other predefined inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>